| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 24, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,000 | $162.47 | $35,743,217.60 | - | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 1,934 | $99.45 | $192,329.14 | -7.2% | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 1,934 | $99.47 | $192,376.33 | -17.0% | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 1,934 | $99.45 | $192,337.85 | -12.7% | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,934 | $99.49 | $192,415.98 | -6.9% | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 1,934 | $99.47 | $192,376.72 | -2.0% | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 2,906 | $99.45 | $289,015.65 | -0.7% | |
| Apr 23, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 230,000 | $160.12 | $36,826,586.81 | - | |
| Apr 23, 2020 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 40,000 | $67.65 | $2,706,000.00 | -1.5% | |
| Apr 21, 2020 | KNSA Kiniksa Pharmaceuticals International, Plc | Beetham Thomas W. | EVP &Chief Legal Officer | Sell | 49,941 | $19.10 | $953,974.86 | -35.1% | |
| Apr 20, 2020 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 37,423 | $66.82 | $2,500,531.00 | -35.3% | |
| Apr 16, 2020 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 20,000 | $62.47 | $1,249,400.00 | -1.5% | |
| Apr 16, 2020 | BSPK Bespoke Extracts, Inc. | Noel Niquana Monique | Director, 10% Owner | Sell | 1 | $24,000.00 | $24,000.00 | -100% | |
| Apr 15, 2020 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 8,632 | $94.65 | $817,017.94 | -42.7% | |
| Apr 15, 2020 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 35,869 | $62.49 | $2,241,615.60 | -0.9% | |
| Apr 14, 2020 | LLY Eli Lilly & Co | Shah Aarti S. | SVP &CIO | Sell | 2,000 | $150.00 | $300,000.00 | -9.5% | |
| Apr 9, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 230,000 | $145.42 | $33,445,541.85 | -0.1% | |
| Apr 9, 2020 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 61,078 | $61.40 | $3,750,475.36 | -1.4% | |
| Apr 7, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 172,315 | $143.20 | $24,676,281.41 | - | |
| Apr 7, 2020 | ZTS Zoetis Inc. | Trawicki Roman48 | Executive Vice President | Sell | 5,499 | $130.00 | $714,870.00 | -65.9% | |
| Apr 7, 2020 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 42,576 | $60.59 | $2,579,575.36 | -1.5% | |
| Apr 6, 2020 | EBS Emergent Biosolutions Inc. | Kirk Sean | EVP, Manufacturing &Tech Ops | Sell | 16,094 | $60.00 | $965,640.00 | -29.9% | |
| Apr 6, 2020 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 7,972 | $60.00 | $478,320.00 | -9.9% | |
| Apr 6, 2020 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 1,179 | $120.00 | $141,480.00 | -6.7% | |
| Apr 6, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 15,962 | $142.73 | $2,278,321.70 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.